Submit Clinical Comparative Data: CDSCO panel tells Abbott Healthcare On Metronidazole ER Tablet
New Delhi: Citing that the drug major Abbott Healthcare did not present any comparative clinical data of proposed drug product, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has opined the firm to submit comparative clinical data of proposed drug product i.e. Metronidazole Extended Release Tablets 600mg (Proposed dose: 2 x 600mg OD) with Metronidazole conventional Tablets 400mg (TS) with respect to proposed additional indication.
This came after the firm presented the proposal for the manufacture and marketing of Metronidazole Extended-Release Tablets 600mg for a proposed additional indication along with additional clinical and published data in support of additional indication before the committee.
Metronidazole is a nitroimidazole used to treat trichomoniasis, amebiasis, inflammatory lesions of rosacea, and bacterial infections, as well as prevent postoperative infections.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.